This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
BEACON was a randomized, quadruple-masked, phase 3, parallel-group treatment study in patients with chronic obstructive pulmonary disease. The study compared QVA149 with concurrent administration of QAB149 and NVA237, with trough FEV1 after 28 days of blinded treatment serving as the registered primary endpoint.
| Feature | BEACON |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Condition | Chronic Obstructive Pulmonary Disease |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | Quadruple |
| Primary purpose | Treatment |
| Enrollment | 193 |
| Number of arms | 2 |
| Study period | Start date: 2012-05; primary completion date: 2012-12 |
| Lead sponsor | Novartis Pharmaceuticals |
| Sponsor type | Industry |
| ClinicalTrials.gov | NCT01529632 |
2. Clinical Question
The clinical question was whether the combination product QVA149 could be evaluated against the concurrent administration of the individual components QAB149 and NVA237 in patients with chronic obstructive pulmonary disease, with pulmonary function after 28 days of blinded treatment measured through trough FEV1.
Population
Patients with chronic obstructive pulmonary disease.
Intervention
QVA149.
Comparator
Concurrent administration of QAB149 and NVA237.
Primary question
How does trough FEV1 after 28 days of blinded treatment compare between QVA149 and concurrent QAB149 plus NVA237?
3. Trial Design
QVA149
- QVA149 was the combination-product intervention.
- The primary endpoint was assessed after 28 days of blinded treatment.
- Serious adverse events: 4 affected / 90 at risk.
Concurrent individual components
- QAB149 and NVA237 were administered concurrently.
- The primary endpoint was assessed after 28 days of blinded treatment.
- Serious adverse events: 6 affected / 103 at risk.
4. Design Features and Statistical Structure
These features are statistically important because the analysis is not simply a comparison of two raw averages. The registry specifies a mixed model that adjusts the Day 29 trough FEV1 comparison for baseline FEV1 and several prespecified baseline or study-site factors.
5. Primary Endpoint
| Endpoint | Time frame | Registry definition |
|---|---|---|
| Trough Forced Expiratory Volume in 1 Second (FEV1) After 28 Days of Blinded Treatment | Day 29 | Spirometry was conducted according to internationally accepted standards. Trough FEV1 is defined as the average of the 23 hour 15 minute and 23 hour 45 minute post-dose FEV1 readings measured at day 29, after 28 days of treatment. |
What makes this a continuous endpoint?
FEV1 is a quantitative pulmonary-function measurement. Unlike a time-to-event endpoint, it does not require censoring or a Kaplan-Meier curve. The statistical question is instead whether the treatment groups differ in their adjusted mean trough FEV1 at the specified assessment time.
The registry defines the endpoint from two post-dose FEV1 measurements rather than relying on a single reading. This creates a prespecified summary of the late post-dose pulmonary-function measurements used for the Day 29 endpoint.
6. Statistical Methodology
Mixed model for trough FEV1
The registry specifies a mixed model with trough FEV1 as the outcome and treatment, baseline FEV1, FEV1 reversibility components, baseline smoking status, baseline ICS use, country, and center nested within country as model terms.
| Model component | Role in the registered model |
|---|---|
| Treatment | Estimates the treatment-group comparison of interest. |
| Baseline FEV1 | Adjusts the comparison for baseline pulmonary function. |
| FEV1 reversibility components | Accounts for the specified FEV1 reversibility components in the primary model. |
| Baseline smoking status | Adjusts for baseline smoking status. |
| Baseline ICS use | Adjusts for baseline inhaled corticosteroid use. |
| Country | Accounts for country in the model. |
| Center nested within country | Center is included as a random effect nested within country. |
| Error | Represents residual variation not explained by the specified model terms. |
Why use a mixed model?
A mixed model is useful when observations are influenced by both measured covariates and sources of clustering. Here, the registry explicitly identifies treatment and baseline variables as model terms and treats center nested within country as a random effect.
The model therefore separates the treatment comparison from several other sources of variation that could contribute to differences in trough FEV1. Baseline adjustment can also improve precision when the baseline measurement is strongly related to the follow-up measurement.
Fixed effects and the random center effect
The registry distinguishes the variables included directly in the model from center, which was included as a random effect nested within country. Conceptually, fixed effects estimate the systematic contribution of specified variables, whereas a random effect represents variation associated with the clustering structure.
The equation is a direct conceptual representation of the model terms specified in the registry. Center nested within country is treated as a random effect.
7. Posted Results and Analysis Status
The ClinicalTrials.gov record indicates that results have been posted and identifies the primary endpoint as trough FEV1 after 28 days of blinded treatment, assessed on Day 29. However, the record does not contain a posted formal statistical analysis for that endpoint.
| Primary endpoint | Posted result status | Registered statistical approach |
|---|---|---|
| Trough FEV1 After 28 Days of Blinded Treatment | No treatment-effect estimate, confidence interval, or p-value is included in the posted statistical analyses. | Mixed model with treatment, baseline FEV1, FEV1 reversibility components, baseline smoking status, baseline ICS use, country, center nested within country, and error; center was a random effect nested within country. |
What can be concluded from the posted information?
The registry establishes what was measured, when it was measured, and how the primary endpoint was specified for statistical analysis. It does not provide a treatment-effect estimate, confidence interval, or p-value in the posted statistical analyses.
For a continuous endpoint such as trough FEV1, the principal inferential quantity would ordinarily be the adjusted treatment difference generated by the prespecified mixed model, accompanied by an uncertainty interval and an appropriate hypothesis test. Those quantities are not included in the posted statistical analyses.
8. Statistical Methods Explained
Why was baseline FEV1 included in the model?
Baseline FEV1 is a direct measure of pulmonary function before the Day 29 endpoint. Including it as a model covariate adjusts the treatment comparison for baseline pulmonary-function differences and can improve statistical precision when baseline FEV1 explains variation in follow-up FEV1.
Why average the 23 hour 15 minute and 23 hour 45 minute measurements?
The registry defines trough FEV1 as the average of these two specified post-dose measurements. Using their average creates one prespecified endpoint value for each participant and reduces reliance on either individual measurement alone.
What does the treatment term estimate?
In this mixed-model framework, the treatment term represents the adjusted difference between the randomized treatment groups after accounting for the other specified model terms. For a continuous FEV1 endpoint, the treatment effect is naturally expressed on the FEV1 measurement scale.
Why include center as a random effect?
Patients treated at the same center can share characteristics related to clinical practice, measurement procedures, or local study implementation. Treating center nested within country as a random effect allows the model to account for center-level variation without treating every center effect as a separate fixed parameter.
Why include country as a model term?
Country can capture systematic differences among study settings. Including country in the model helps distinguish the treatment comparison from geographic differences represented by the study sites.
What is the difference between an adjusted and unadjusted comparison?
An unadjusted comparison would focus directly on the observed treatment-group means. The registered mixed model instead estimates the treatment comparison after accounting for prespecified baseline and study-setting variables. The adjusted comparison is therefore the quantity aligned with the registered primary statistical model.
Why is the p-value not the effect size?
A p-value addresses the compatibility of the observed data with a specified null hypothesis under the statistical model. It does not describe the magnitude of the treatment difference. For a continuous FEV1 endpoint, the treatment difference itself is the effect-size quantity, while a confidence interval describes its statistical precision.
9. Serious Adverse Events
The registry reports serious adverse events by randomized arm. The available figures are presented as the number affected divided by the number at risk.
| Safety measure | QVA149 | QAB149 + NVA237 |
|---|---|---|
| Serious adverse events | 4 / 90 | 6 / 103 |
QVA149
4 patients were affected among 90 at risk for the reported serious-adverse-event measure.
QAB149 + NVA237
6 patients were affected among 103 at risk for the reported serious-adverse-event measure.
These figures are descriptive safety counts. They should not be interpreted as evidence of a treatment difference without an accompanying prespecified statistical safety analysis, uncertainty assessment, and definition of the relevant safety population.
10. Statistical Interpretation of the Primary Endpoint
Trough FEV1 measures pulmonary function at the specified late post-dose time point on Day 29. The registry defines it as the average of the 23 hour 15 minute and 23 hour 45 minute post-dose FEV1 readings after 28 days of treatment.
The mixed model adjusts the treatment comparison for baseline FEV1, FEV1 reversibility components, baseline smoking status, baseline ICS use, country, and center nested within country. This means the primary comparison is intended to reflect the treatment effect after accounting for these prespecified sources of variation.
The posted statistical analyses do not contain a numerical treatment estimate, confidence interval, or p-value for trough FEV1. Consequently, the registry information establishes the analysis framework but does not provide the numerical inferential result for the primary endpoint.
11. Understanding the Mixed-Model Comparison
The central statistical idea in BEACON is adjustment rather than simple subtraction of two raw endpoint means. Suppose \(Y_i\) represents the Day 29 trough FEV1 measurement for participant \(i\). The registered model conceptually separates the observed outcome into a treatment component, baseline and other covariate contributions, center-level variation, and residual error.
The expression illustrates the structure of the registered model rather than supplying numerical coefficients that are not present in the posted statistical analyses.
This distinction is important. Two treatment groups can have different observed mean FEV1 values for several reasons. Some of that difference may reflect baseline pulmonary function, smoking status, inhaled corticosteroid use, geographic setting, or center-level variation. The registered mixed model is designed to account for those factors when estimating the treatment comparison.
Adjusted treatment effect versus raw difference
An adjusted treatment effect can differ from a raw difference in observed means because the model uses information from the covariates and the clustering structure. The adjusted estimate is therefore tied to the statistical model, not simply to a visual comparison of two group averages.
Precision matters
Even if an estimated treatment difference were available, the estimate alone would not fully describe the evidence. A confidence interval would indicate the precision of the estimate, while a p-value would address the specified hypothesis test. Effect magnitude, precision, and statistical evidence are distinct quantities.
12. Randomization and Causal Interpretation
Randomization is one of the most important design features of BEACON. With randomized allocation, treatment assignment is determined independently of the participant's observed baseline characteristics in expectation, allowing between-group differences to be interpreted causally under the usual assumptions of randomized-trial analysis.
Why randomization helps
Random allocation helps balance measured and unmeasured prognostic factors between treatment groups in expectation.
Why adjustment still helps
Even in a randomized trial, baseline covariate adjustment can improve precision and account for observed variation in the outcome.
Why masking matters
Quadruple masking reduces opportunities for knowledge of treatment assignment to influence study conduct or assessment.
Why the endpoint definition matters
A prespecified Day 29 trough definition makes the primary measurement rule explicit before interpretation of the treatment comparison.
13. Study Timeline
Study start
The BEACON study began in May 2012.
Blinded treatment period for the primary endpoint
The registered primary endpoint was measured after 28 days of blinded treatment.
Primary FEV1 assessment
Trough FEV1 was defined from the average of the 23 hour 15 minute and 23 hour 45 minute post-dose FEV1 readings.
Primary completion
The registry lists December 2012 as the primary completion date.
14. Statistical Interpretation vs Clinical Interpretation
Statistical interpretation
The primary endpoint is a continuous Day 29 FEV1 measure analyzed under a prespecified mixed-model framework. The model includes treatment, baseline and other specified covariates, country, and a random center effect nested within country.
Clinical interpretation
Trough FEV1 provides a quantitative measure of pulmonary function at the specified late post-dose time point. The clinical meaning of a treatment difference depends on the magnitude of the observed difference and its clinical context.
The distinction is important because a statistically estimated difference is not automatically equivalent to a clinically important difference. Clinical interpretation requires the actual treatment estimate and an understanding of what magnitude of FEV1 change is meaningful in the population being studied.
15. Limitations and Interpretation Issues
- No posted inferential estimate: the ClinicalTrials.gov record does not provide a treatment-effect estimate, confidence interval, or p-value in its posted statistical analyses for the primary endpoint.
- Mixed-model dependence: the interpretation of the treatment effect depends on the specified mixed-model structure, including its covariates and random center effect.
- Baseline adjustment: adjusted treatment effects should not be confused with simple unadjusted differences between observed group averages.
- Center clustering: patients within the same center may have correlated measurements or shared study conditions, which is why center is incorporated as a random effect nested within country.
- Continuous endpoint: trough FEV1 provides information on pulmonary function but does not by itself summarize every dimension of treatment benefit or safety.
- Safety interpretation: the serious-adverse-event counts are descriptive and should not be converted into a comparative safety conclusion without a fuller prespecified safety analysis.
- Registry-level detail: the available record identifies the primary endpoint and its model specification but does not provide the numerical model output needed for a complete inferential comparison.
16. Why This Trial Matters Statistically
BEACON is a useful teaching example because it illustrates a different statistical pattern from trials dominated by survival analysis. The primary endpoint is a continuous physiologic measurement, and the registry specifies a covariate-adjusted mixed model rather than a Kaplan-Meier or Cox proportional-hazards analysis.
| Concept | How it appears in BEACON |
|---|---|
| Randomization | Patients were randomly allocated to one of two treatment arms. |
| Parallel design | The two treatment groups were evaluated as parallel arms. |
| Quadruple masking | The study used quadruple masking. |
| Continuous endpoint | Trough FEV1 is a quantitative pulmonary-function outcome. |
| Repeated measurement definition | Trough FEV1 is the average of two specified post-dose measurements on Day 29. |
| Covariate adjustment | Baseline FEV1 and other specified baseline factors enter the mixed model. |
| Mixed model | The primary endpoint is analyzed using the registry-specified mixed-model structure. |
| Random effect | Center is included as a random effect nested within country. |
| Geographic adjustment | Country is included as a model term. |
| Safety description | Serious adverse events are reported as affected / at risk by arm. |
17. A Practical Reading of the Primary Analysis
A reader approaching the BEACON primary endpoint can think through the analysis in four stages.
1. Define the outcome
Use the registered trough FEV1 definition based on the two specified post-dose measurements on Day 29.
2. Compare treatment groups
Estimate the treatment effect within the randomized parallel-group comparison.
3. Adjust the comparison
Use the registered mixed model incorporating baseline FEV1, reversibility components, smoking status, ICS use, country, and center nested within country.
4. Quantify uncertainty
Normally, the adjusted treatment estimate would be accompanied by a confidence interval and hypothesis-test result.
The fourth step is where the posted registry information is incomplete for inferential interpretation: the numerical statistical output is not contained in the posted statistical analyses. The model specification is available, but the corresponding estimate and uncertainty measures are not.
18. Safety and Efficacy Are Different Statistical Questions
BEACON illustrates why efficacy and safety should be analyzed separately. The primary efficacy endpoint is a continuous FEV1 measurement, while the reported serious-adverse-event information is a count of affected participants relative to those at risk.
| Domain | Measure in BEACON | Statistical character |
|---|---|---|
| Efficacy | Trough FEV1 on Day 29 | Continuous outcome analyzed using a mixed model |
| Safety | Serious adverse events | Descriptive affected / at-risk counts by arm |
A difference in a continuous pulmonary-function endpoint and a difference in adverse-event frequency answer different questions. They should not be combined into a single numerical judgment about the trial without a prespecified framework for weighing efficacy and safety.
19. What the Registry Establishes
The ClinicalTrials.gov record establishes a clear statistical framework for the primary endpoint. BEACON was randomized and parallel, used quadruple masking, enrolled 193 participants, and compared QVA149 with concurrent QAB149 plus NVA237. The primary endpoint was trough FEV1 after 28 days of blinded treatment, measured on Day 29.
The registry further specifies a mixed model containing treatment, baseline FEV1, FEV1 reversibility components, baseline smoking status, baseline ICS use, country, center nested within country, and error, with center included as a random effect nested within country.
That information is enough to understand the intended structure of the primary analysis. It is not enough to state the numerical treatment effect because the posted statistical analyses do not include the corresponding estimate, confidence interval, or p-value.
20. Sources
- ClinicalTrials.gov: BEACON — NCT01529632.
Continue through the Clinical Biostats clinical trial library
Explore additional clinical trial statistical analyses and educational explanations of study design, endpoints, modeling, and interpretation.
21. Record Summary
BEACON provides a concise example of covariate-adjusted analysis of a continuous clinical endpoint. Its randomized, quadruple-masked, parallel-group phase 3 design compared QVA149 with concurrent QAB149 and NVA237 in chronic obstructive pulmonary disease. The primary endpoint was trough FEV1 after 28 days of blinded treatment, defined as the average of the 23 hour 15 minute and 23 hour 45 minute post-dose FEV1 measurements on Day 29.
The statistical model is particularly instructive. Rather than relying only on an unadjusted treatment-group comparison, the registered analysis incorporates baseline FEV1, FEV1 reversibility components, baseline smoking status, baseline ICS use, country, and center nested within country, with center treated as a random effect. This structure demonstrates how randomized trials can use prespecified covariate adjustment and hierarchical modeling to obtain a more precise treatment comparison.
The registry also reports serious adverse events of 4 / 90 for QVA149 and 6 / 103 for QAB149 plus NVA237. These are descriptive safety figures and are distinct from the primary continuous efficacy endpoint.